> Details

Schupp, Tobias; Behnes, Michael; Ellguth, Dominik; Müller, Julian; Reiser, Linda; Bollow, Armin; Taton, Gabriel; Reichelt, Thomas; Engelke, Niko; Kim, Seung-hyun; Nienaber, Christoph; Akin, Muharrem; Mashayekhi, Kambis; Bertsch, Thomas; Borggrefe, Martin; Akin, Ibrahim

Impact of Different Pharmacotherapies on Long-Term Outcomes in Patients with Electrical Storm

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Impact of Different Pharmacotherapies on Long-Term Outcomes in Patients with Electrical Storm
  • Contributor: Schupp, Tobias; Behnes, Michael; Ellguth, Dominik; Müller, Julian; Reiser, Linda; Bollow, Armin; Taton, Gabriel; Reichelt, Thomas; Engelke, Niko; Kim, Seung-hyun; Nienaber, Christoph; Akin, Muharrem; Mashayekhi, Kambis; Bertsch, Thomas; Borggrefe, Martin; Akin, Ibrahim
  • imprint: S. Karger AG, 2019
  • Published in: Pharmacology
  • Language: English
  • DOI: 10.1159/000496228
  • ISSN: 0031-7012; 1423-0313
  • Keywords: Pharmacology ; General Medicine
  • Origination:
  • Footnote:
  • Description: <jats:p>&lt;b&gt;&lt;i&gt;Objective:&lt;/i&gt;&lt;/b&gt; The study sought to assess the long-term prognostic impact of different pharmacotherapies, including angiotensin-converting enzyme inhibitor-inhibitor/angiotensin receptor blocker (ACEi/ARB), statins, and amiodarone in patients with electrical storm (ES). &lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Data regarding the outcome of patients with ES is limited. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Consecutive patients with ES from 2002 to 2016 were included. Patients on ACEi/ARB were compared to patients without ACEi/ARB, respectively, for statin and amiodarone therapy. The primary prognostic endpoint was all-cause mortality at 4 years. Secondary endpoints comprised ES recurrences, rehospitalization, and major adverse cardiac events (MACE) at 4 years. Kaplan-Meier survival curves and multivariable Cox regression analyses were applied. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; A total of 84 consecutive patients surviving episodes of ES was included. Beta-blocker was given in 95%, ACEi/ARB in 80%, statin in 60%, and amiodarone in 54%. ACEi/ARB patients were associated with improved all-cause mortality at 4 years (mortality rate 34 vs. 65%, log rank &lt;i&gt;p&lt;/i&gt; = 0.018; HR 0.428; 95% CI 0.208–0.881; &lt;i&gt;p&lt;/i&gt; = 0.021), as well as improved freedom from MACE. In contrast, statin and amiodarone therapy had no impact on long-term outcomes in ES patients. &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; ACEi/ARB therapy is associated with improved survival and MACE in patients with ES, whereas statins and amiodarone therapy had no impact on long-term prognostic endpoints.</jats:p>